1.Previous
3.Next

in chemotherapy regimens with the aim to prevent mild-neutropenia.

G-CSF was first trialled as a therapy for neutropenia induced by chemotherapy in 1988. The treatment was well tolerated and a dose-dependent rise in circulating neutrophils was noted.

A study in mice has shown that G-CSF may decrease bone mineral density.

G-CSF administration has been shown to attenuate the telomere loss associated with chemotherapy.

Use in drug-induced neutropenia

1.Previous
3.Next